Agentic AI turns wasted windshield time into productive CRM updates and deploys always-on virtual reps to support providers ...
New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.
FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, ...
FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy (pMN) at risk ...
Sustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for ...
Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.
Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from ...
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter ...
The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per ...
A $3.5B Lehigh Valley buildout will add U.S. injectable capacity for future obesity therapies, explicitly including investigational retatrutide, with operations expected to start in 2031. Retatrutide, ...
FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. FDA has granted ...
As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting ...